Clinical Features and Risk Factors of Enfortumab Vedotin–Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study)

Documenti analoghi

• Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum‐Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study
  di: Hiroki Shimoda, et al.
  Pubblicazione: (2026)
• Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First‐Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real‐World Study ( YUSHIMA Study)
  di: Rie Muta, et al.
  Pubblicazione: (2026)
• Real‐World Outcomes of First‐Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment ( YUSHIMA Study)
  di: Tomoki Kimura, et al.
  Pubblicazione: (2025)
• Real‐World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: A Propensity‐Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis
  di: Yosuke Yasuda, et al.
  Pubblicazione: (2026)
• Editorial Comment to “Clinical Features and Risk Factors of Enfortumab Vedotin‐Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study)”
  di: Makito Miyake
  Pubblicazione: (2026)